He Xi-Ran, Han Shu-Yan, Li Ping-Ping
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Traditional Chinese and Western Medicine, Peking University School of Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Chin J Integr Med. 2017 May;23(5):323-330. doi: 10.1007/s11655-016-2736-2. Epub 2016 Dec 27.
Owing to its unique superiority in improving quality of life and prolonging survival time among advanced lung cancer patients, Chinese medicine (CM) has, in recent years, received increased attentions worldwide. We utilized a bibliometric statistical method based on MEDLINE/GoPubMed to conduct a comprehensive analysis of the current application status of CM in lung cancer, by including annual and accumulated publications, origin distribution of countries and journals, and keywords with a higher frequency score. Then the relevant clinical trials and mechanistic studies were systematically summarized within the field according to research types. We have raised potential problems and provided potentially useful reference information that could guide similar studies in the future. The basic experimental results are highly consistent with clinical trials, leading us to conclude that CM can offer better overall therapeutic benefits when used in combination with routine Western medicine for patients with advanced lung cancer.
由于中医药在改善晚期肺癌患者生活质量和延长生存时间方面具有独特优势，近年来在全球范围内受到越来越多的关注。我们利用基于MEDLINE/GoPubMed的文献计量统计方法，通过纳入年度和累积出版物、国家和期刊的来源分布以及频率得分较高的关键词，对中医药在肺癌中的当前应用状况进行了全面分析。然后根据研究类型对该领域的相关临床试验和机制研究进行了系统总结。我们提出了潜在问题，并提供了可能有用的参考信息，以指导未来的类似研究。基础实验结果与临床试验高度一致，这使我们得出结论，对于晚期肺癌患者，中医药与常规西药联合使用可提供更好的整体治疗效果。
